FLEXBUMIN 25% [Albumin (Human)], 25% Solution

The first and only albumin in a flexible container.

Efficient

Takes up 60% less space than glass bottles on shelves¹* and helps optimize storage in Pyxis units
Weighs 40% less than glass¹*
*Based on comparison with BUMINATE 25% [Albumin (Human)] Solution

Safety

No risk of glass breakage
Environmentally friendly and is the first and only medical product certified by the Carbon Trust for carbon footprint reduction²

Simple

1-2-3 (suspend, remove, attach) preparation streamlines infusion set-up³
Eyelet allows easier handling⁴
Flexibility to use with vented or non-vented standard IV administration sets³

CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

FLEXBUMIN: Putting innovation to work for you

FLEXBUMIN integrates two of our company's core competencies: plasma therapeutics and innovative medication delivery systems.

Our proprietary GALAXY container manufacturing process is the only system capable of aseptically filling albumin into flexible containers, which have no latex, PVC, DEHP, or DEHA⁵
The end result represents an efficient way for hospitals to deliver albumin therapy…and a reliable supply from a manufacturer that customers can trust

FLEXBUMIN 25% [Albumin (Human)]

FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, and for use during or prior to cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).

Important Risk Information for FLEXBUMIN 25%

FLEXBUMIN 25% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.

Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered.

Do not use Sterile Water for Injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for FLEXBUMIN 25%. Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.

FLEXBUMIN 25% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.

FLEXBUMIN 25% must be administered intravenously at a rate not to exceed 1 mL/min to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema.

When 25% albumin is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.

Adverse reactions to FLEXBUMIN 25% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur.

CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please see Preparation for Administration for FLEXBUMIN 25% in the Prescribing Information.

Please review the FLEXBUMIN 25% [Albumin (Human)] Prescribing Information for full prescribing details.

BUMINATE 5% [Albumin (Human)], USP, 5% Solution

BUMINATE 5% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 5% is indicated in hypovolemia, hypoalbuminemia, burns, and cardiopulmonary bypass surgery.

Please see Important Risk Information for BUMINATE 5% and Full Prescribing Information.

BUMINATE 25% [Albumin (Human)], USP, 25% Solution

BUMINATE 25% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 25% is indicated in hypovolemia, hypoalbuminemia, burns, adult respiratory distress syndrome (ARDS), nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).

Please see Important Risk Information for BUMINATE 25% and Full Prescribing Information.

Storage space and weight comparison. Data on file. Baxter Healthcare Corporation.
The Carbon Label Company Limited. Carbon Footprint Certification Letter 2008/000106/001. Carbon Trust; London, England. October 27, 2009.
FLEXBUMIN 25% [Albumin (Human)], 25% Solution. Westlake Village, CA: Baxter Healthcare Corporation; September 2009.
FLEXBUMIN Time and Motion Study. Data on File. Baxter Healthcare Corporation.
GALAXY Container Components. Data on File. Baxter Healthcare Corporation.